Skip to content

Development of a markerless approach to abdominal motion tracking during radiotherapy: an observation-only feasibility study

Development of an AI-guided approach to markerless tracking of abdominal targets and organs-at-risk (OARs) during radiotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12626001035314
Acronym
MAMBA (Markerless Abdominal Motion tracking Based on Artificial intelligence)
Enrollment
1
Registered
2026-08-24
Start date
2026-05-18
Completion date
2027-05-04
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Due to normal functional processes such as breathing and digestion, abdominal tumours and organs can move during radiotherapy. The purpose of this study is to determine whether a new software using artificial intelligence (AI) can be used during radiotherapy to track organ motion for more accurate treatment. Who is it for? You may be eligible for this study if you are an adult who is receiving radiotherapy for treatment of an upper abdominal cancer, for example pancreatic cancer, liver cancer or kidney cancer. Study details All participants in this study will continue to undergo their usual radiotherapy treatment schedule. Using AI, we will generate a customised ‘motion model’ specific to each participant. During radiotherapy treatment sessions, additional x-ray imaging will be collected. These images will be used to check the performance of this custom AI model. There will be no follow up of participants and the motion model will not be used to guide or impact treatment of the participant. It is hoped that this study will help researchers understand more about how AI may be safely used during abdominal radiotherapy. This knowledge may help improve the quality of treatment received by cancer patients in the future.

Interventions

This study evaluates a new method to track tumour and organ motion during radiotherapy. Using artificial intelligence, a customised 'motion model' will be created for each participant using their CT images. Depending on the participant’s standard of care treatment, this may involve the collection of 2 additional cone beam computed tomography (CBCT) images for model generation purposes. The model will be loaded into a research software by a Medical Physicist trained in the use of the software. Th

This study evaluates a new method to track tumour and organ motion during radiotherapy. Using artificial intelligence, a customised 'motion model' will be created for each participant using their CT images. Depending on the participant’s standard of care treatment, this may involve the collection of 2 additional cone beam computed tomography (CBCT) images for model generation purposes. The model will be loaded into a research software by a Medical Physicist trained in the use of the software. The research software will be run at the time of treatment to measure the motion of critical structures such as the tumour, pancreas, duodenum, small bowel and/or stomach. X-ray imaging acquired as part of this study will act as inputs to the research software. Note that this is an observation-only study; the output of the research software will not be used to modify the participants' treatment. In the future, it is expected that the radiotherapy treatment team will use a software such as this to better direct the radiation towards the tumour and away from nearby organs based on the motion observed. Participants will undergo additional x-ray imaging during their radiotherapy treatment sessions. This is to 1) enable to use of the research software and 2) to monitor the position of certain organs, to verify the output of each participant's motion model. Organs will be monitored if they are within 2 cm of the treatment area. This additional imaging will be acquired during 5 of the participants' standard treatment sessions, and is expected to extend the length of each treatment session by no more than 10 minutes. It is anticipated that trial data collection will be complete within a 2 week period.

Sponsors

Northern Sydney Local Health District
Lead SponsorGovernment body

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Receiving upper abdominal radiotherapy (pancreas, liver, kidney, adrenal gland) with a planning CT scan. If the site of treatment is not the pancreas, at least one of the specified organs-at-risk (duodenum, small bowel, stomach) must be present within a 2 cm margin of the planning target volume.

Exclusion criteria

Tumour maximum dimension more than 12 cm and minimum dimension less than 1 cm, unable to give informed consent and/or pregnant women.

Outcome results

None listed

Source: ANZCTR · Data processed: Sep 19, 2026